newsfilter
← Latest News
Business Wire·

Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026

INCB161734 (KRAS G12D inhibitor) and INCA338901 (TGFβR2×PD-1 bispecific antibody) data reinforce ongoing and planned registrational trials, including DAWN-303 in pancreatic ductal adenocarcinoma (PDAC) and NEXERA-303